PBH
Price
$62.42
Change
+$0.11 (+0.18%)
Updated
Dec 24 closing price
Capitalization
3B
41 days until earnings call
Intraday BUY SELL Signals
ZTS
Price
$125.49
Change
+$1.95 (+1.58%)
Updated
Dec 24 closing price
Capitalization
55.3B
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PBH vs ZTS

Header iconPBH vs ZTS Comparison
Open Charts PBH vs ZTSBanner chart's image
Prestige Consumer Healthcare
Price$62.42
Change+$0.11 (+0.18%)
Volume$155.04K
Capitalization3B
ZOETIS
Price$125.49
Change+$1.95 (+1.58%)
Volume$2.37M
Capitalization55.3B
PBH vs ZTS Comparison Chart in %
PBH
Daily Signal:
Gain/Loss:
ZTS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PBH vs. ZTS commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBH is a Buy and ZTS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (PBH: $62.42 vs. ZTS: $125.49)
Brand notoriety: PBH: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PBH: 35% vs. ZTS: 45%
Market capitalization -- PBH: $3B vs. ZTS: $55.3B
PBH [@Pharmaceuticals: Generic] is valued at $3B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $55.3B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBH’s FA Score shows that 0 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • PBH’s FA Score: 0 green, 5 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, ZTS is a better buy in the long-term than PBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBH’s TA Score shows that 8 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • PBH’s TA Score: 8 bullish, 2 bearish.
  • ZTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PBH is a better buy in the short-term than ZTS.

Price Growth

PBH (@Pharmaceuticals: Generic) experienced а +0.16% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +2.65% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.58%. For the same industry, the average monthly price growth was +8.11%, and the average quarterly price growth was +22.96%.

Reported Earning Dates

PBH is expected to report earnings on Feb 05, 2026.

ZTS is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($55.3B) has a higher market cap than PBH($3B). ZTS has higher P/E ratio than PBH: ZTS (21.13) vs PBH (15.45). PBH YTD gains are higher at: -20.067 vs. ZTS (-21.956). ZTS has higher annual earnings (EBITDA): 4.04B vs. PBH (357M). ZTS has more cash in the bank: 2.08B vs. PBH (119M). PBH has less debt than ZTS: PBH (1.04B) vs ZTS (7.27B). ZTS has higher revenues than PBH: ZTS (9.4B) vs PBH (1.11B).
PBHZTSPBH / ZTS
Capitalization3B55.3B5%
EBITDA357M4.04B9%
Gain YTD-20.067-21.95691%
P/E Ratio15.4521.1373%
Revenue1.11B9.4B12%
Total Cash119M2.08B6%
Total Debt1.04B7.27B14%
FUNDAMENTALS RATINGS
PBH vs ZTS: Fundamental Ratings
PBH
ZTS
OUTLOOK RATING
1..100
737
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
52100
SMR RATING
1..100
6619
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
7686
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (32) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PBH (84) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than PBH’s over the last 12 months.

PBH's Profit vs Risk Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that PBH’s stock grew somewhat faster than ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PBH (66) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than PBH’s over the last 12 months.

PBH's Price Growth Rating (61) in the Pharmaceuticals Other industry is in the same range as ZTS (63) in the Pharmaceuticals Generic industry. This means that PBH’s stock grew similarly to ZTS’s over the last 12 months.

PBH's P/E Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as ZTS (86) in the Pharmaceuticals Generic industry. This means that PBH’s stock grew similarly to ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBHZTS
RSI
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
52%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 11 days ago
56%
Bullish Trend 11 days ago
55%
Declines
ODDS (%)
Bearish Trend 7 days ago
54%
Bearish Trend 17 days ago
59%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
47%
Aroon
ODDS (%)
Bullish Trend 2 days ago
51%
Bearish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
PBH
Daily Signal:
Gain/Loss:
ZTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GBAT1.610.02
+1.26%
Grayscale Basic Attention Token Trust (BAT)
RPAR21.820.14
+0.63%
RPAR Risk Parity ETF
AESR17.260.07
+0.41%
Anfield US Equity Sector Rotation ETF
QRFT63.280.20
+0.32%
QRAFT AI-Enhanced US Large Cap ETF
DFEM32.990.06
+0.18%
Dimensional Emerging Markets Cr Eq 2 ETF

PBH and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBH has been loosely correlated with PAHC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBH
1D Price
Change %
PBH100%
+0.18%
PAHC - PBH
38%
Loosely correlated
+0.94%
IRWD - PBH
32%
Poorly correlated
+1.56%
AMRX - PBH
31%
Poorly correlated
+0.23%
ZTS - PBH
30%
Poorly correlated
+1.58%
ELAN - PBH
29%
Poorly correlated
+0.72%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+1.58%
ELAN - ZTS
47%
Loosely correlated
+0.72%
VTRS - ZTS
38%
Loosely correlated
+1.83%
PAHC - ZTS
38%
Loosely correlated
+0.94%
AMPH - ZTS
36%
Loosely correlated
+1.36%
PRGO - ZTS
35%
Loosely correlated
+0.51%
More